Cupp EW, Sauerbrey M, Richards F, 2011. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Trop 120 (Suppl 1): S100–S108.
Boatin BA, Richards FO Jr., 2006. Control of onchocerciasis. Adv Parasitol 61: 349–394.
World Health Organization, 2017. Summary of global update on preventive chemotherapy implementation in 2016: crossing the billion. Wkly Epidemiol Rec 92: 589–593.
Herricks JR et al. 2017. The global burden of disease study 2013: what does it mean for the NTDs? PLoS Negl Trop Dis 11: e0005424.
Mectizan Donation Program, 2017. Available at: https://www.mectizan.org/achievements. Accessed December 21, 2017.
Katabarwa M, Richards F, 2014. Twice-yearly ivermectin for onchocerciasis: the time is now. Lancet Infect Dis 14: 373–374.
Diawara L et al. 2009. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 3: e497.
Kelly-Hope LA, Unnasch TR, Stanton MC, Molyneux DH, 2015. Hypo-endemic onchocerciasis hotspots: defining areas of high risk through micro-mapping and environmental delineation. Infect Dis Poverty 4: 36.
Mectizan Donation Program, 1996. Central Nervous System (CNS) Complications of Loiasis and Adverse CNS Events Following Treatment: Report of an Invited Consultation. October 2–3, 1995, Atlanta, GA: Mectizan Donation Program.
Boussinesq M, Gardon J, 1997. Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection. Ann Trop Med Parasitol 91: 573–589.
Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP, 1998. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am J Trop Med Hyg 58: 461–469.
Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD, 2008. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg 78: 546–551.
Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M, 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 18–22.
Addiss DG, Rheingans R, Twum-Danso NA, Richards FO, 2003. A framework for decision-making for mass distribution of Mectizan(R) in areas endemic for Loa loa. Filaria J 2 (Suppl 1): S9.
Twum-Danso NA, 2003. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2 (Suppl 1): S7.
Diggle PJ et al. 2007. Spatial modelling and the prediction of Loa loa risk: decision making under uncertainty. Ann Trop Med Parasitol 101: 499–509.
Tekle AH, Zoure H, Wanji S, Leak S, Noma M, Remme JH, Amazigo U, 2011. Integrated rapid mapping of onchocerciasis and loiasis in the Democratic Republic of Congo: impact on control strategies. Acta Trop 120 (Suppl 1): S81–S90.
Wanji S, 2001. Rapid Assessment Procedures for Loiasis: Report of a Multi-centre Study. Geneva, Switzerland: UNDP/World Bank/World Health Organization Special Programme for Research & Training in Tropical Diseases.
Wanji S, Akotshi DO, Mutro MN, Tepage F, Ukety TO, Diggle PJ, Remme JH, 2012. Validation of the rapid assessment procedure for loiasis (RAPLOA) in the Democratic Republic of Congo. Parasit Vectors 5: 25.
Zoure HG, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JH, 2011. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 5: e1210.
D’Ambrosio MV et al. 2015. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med 7: 286re4.
Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M, 2009. Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events. Am J Trop Med Hyg 81: 1056–1061.
Kamgno J et al. 2017. A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas. N Engl J Med 377: 2044–2052.
Federal Ministry of Health, Nigeria, 2017. Nigeria Onchocerciasis Elimination Plan. Abuja, Nigeria: Federal Ministry of Health.
Takougang I et al. 2002. Rapid assessment method for prevalence and intensity of Loa loa infection. Bull World Health Organ 80: 852–858.
Hassan AA, Akinsanya B, Iyase N, Owagboriaye FO, 2011. Assessment of loiasis and outcomes of ivermectin masstreatment in Ijebu-North, Nigeria. Korean J Parasitol 49: 153–159.
Anonymous, 2016. Communiqué of the 5th Onchocerciasis Elimination Committee (NOEC). December 14–16, 2016, Barcelona Hotel, Abuja, Nigeria.
World Health Organization/Department of Control of Neglected Tropical Diseases, 2012. Provisional Strategy for Interrupting Lymphatic Filariasis Transmission in Loiasis-endemic Countries: Report of the Meeting on Lymphatic Filariasis, Malaria and Integrated Vector Management. Accra, Ghana: WHO.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||1686||302||16|
Ivermectin treatment can cause central nervous system adverse events (CNS-AEs) in persons with very high-density Loa loa microfilaremia (≥ 30,000 mf/mL blood). Hypoendemic onchocerciasis areas where L. loa is endemic have been excluded from ivermectin mass drug administration programs (MDA) because of the concern for CNS AEs. The rapid assessment procedure for L. loa (RAPLOA) is a questionnaire survey to assess history of eye worm. If ≥ 40% of respondents report eye worm, this correlates with ≥ 2% prevalence of very high-density loiasis microfilaremia, posing an unacceptable risk of CNS-AEs after MDA. In 2016, we conducted a L. loa study in 110 ivermectin-naïve, suspected onchocerciasis hypoendemic villages in southern Nigeria. In previous RAPLOA surveys these villages had prevalences between 10% and 67%. We examined 10,605 residents using the LoaScope, a cell phone–based imaging device for rapidly determining the microfilaria (mf) density of L. loa infections. The mean L. loa village mf prevalence was 6.3% (range 0–29%) and the mean individual mf count among positives was 326 mf/mL. The maximum individual mf count was only 11,429 mf/mL, and among 2,748 persons sampled from the 28 villages with ≥ 40% RAPLOA, the ≥ 2% threshold of very high Loa mf density could be excluded with high statistical confidence (P < 0.01). These findings indicate that ivermectin MDA can be delivered in this area with extremely low risk of L. loa–related CNS-AEs. We also concluded that in Nigeria the RAPLOA survey methodology is not predictive of ≥ 2% prevalence of very high-density L. loa microfilaremia.
Financial support: D. A. F. reports grants from Bill & Melinda Gates Foundation, during the conduct of the study; In addition, Fletcher has a patent High Numerical Aperture Telemicroscopy Apparatus (US Patents 8,743,194 and 8,786,695) licensed to Thermo Fisher Scientific; CellScope, Inc., and a patent Automated Hardware and Software for Mobile Microscopy (US Patent pending). M. D. reports grants from Bill & Melinda Gates Foundation, during the conduct of the study; In addition, D’Ambrosio has a patent Automated Hardware and Software for Mobile Microscopy (US Patent pending).
Authors’ addresses: Emmanuel Emukah, Carter Center, Owerri, Nigeria, E-mail: email@example.com. Lindsay J. Rakers, Emily Griswold, and Frank O. Richards, Carter Center, Atlanta, GA, E-mails: firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Barminas Kahansim, Emmanuel S. Miri, and Cephas Ityonzughul, Carter Center, Jos, Nigeria, E-mails: email@example.com, firstname.lastname@example.org, and cephas.Ityonzughul@cartercenter.org. Bertram E. B. Nwoke, Parasitology Department, Imo State University, Owerri, Nigeria, E-mail: email@example.com. Yisa Saka, Ifeoma Anagbogu, and Emmanuel Davies, Federal Ministry of Health, Abuja, Nigeria, E-mails: firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Michael D’Ambrosio, Matthew Bakalar, and Daniel A. Fletcher, University of Berkeley, Berkeley, CA, E-mails: email@example.com, firstname.lastname@example.org, and email@example.com. Thomas Nutman, National Institute of Health, Bethesda, MD, E-mail: firstname.lastname@example.org. Joseph Kamgno, Centre for Research on Filariasis, Yaoundé, Cameroon and Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaoundé, Cameroon, E-mail: email@example.com.